Elsevier Announces Its Official Collaboration with ROSATOM, Russia’s Leading Atomic Energy Corporation

Collaboration provides ROSATOM with access to ScienceDirect and Scopus, fostering international expertise and the launch of new technologies and innovations in safe nuclear energy

Moscow, February 5, 2013 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today its collaboration with Russia’s State Atomic Energy Corporation (ROSATOM), providing ROSATOM’s major affiliated research organizations with access to Elsevier’s ScienceDirect and Scopus.

ROSATOM unites a number of Russia’s key enterprises focusing on atomic power engineering, nuclear and radiation safety and fundamental and applied research in the creation of structural materials and technologies. The corporation actively participates in international energy research and develops innovative technologies in water treatment, new isotopes for medicine and in superconductivity. By providing more than ten of its key enterprises with access to ScienceDirect and Scopus, ROSATOM will help these institutes to significantly advance and accelerate their research and innovation in atomic energy.

Svetlana Sheveleva, Deputy Director on Innovation Complex at ROSATOM said, “As one of the world’s leaders in atomic energy, we aim to be a world-class research organization. Our research leads to the discovery of new technologies in medicine, material science and other actual fundamental and applied areas. Without access to world-class scientific information, resources and tools, this would not be possible. Our collaboration with Elsevier helps us reach our objectives.”

Igor Osipov, PhD, Regional Director at Elsevier Russia and Belarus added, “ROSATOM is one of the global leaders in safe nuclear energy research and we have collaborated with their flagship R&D think tank – Russian Federal Nuclear Center (RFNC–VNIIEF) for many years. We are happy to take this collaboration to the next level by providing access to ScienceDirect and Scopus to the entire network of R&D organization within ROSATOM. Through our agreement with ROSATOM, Elsevier can contribute to the development of high quality research and innovation in the Russian and international energy sector.”

# # #

About ROSATOM
The State Atomic Energy Corporation ROSATOM incorporates more than 250 enterprises and scientific institutions, including all civil nuclear companies of Russia, nuclear weapons complex’s facilities, research organizations and the world’s only nuclear-propelled fleet. ROSATOM is the largest utility in Russia which produces more than 40 % of electricity in the country’s European part. ROSATOM holds leading positions in the world market of nuclear technologies being the 1-st in the world simultaneous nuclear build abroad; 2-nd in uranium reserves and 5-th in uranium mining; 4-th in nuclear electricity generation, while providing 40% of the world uranium enrichment services and 17% of the world nuclear fuel market. ROSATOM is also tasked to fulfill Russia's international obligations in the field of the peaceful uses of atomic energy and nuclear nonproliferation regime.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Galina Yakshonak
Elsevier, Russia
+7 985 72 779 67
g.yakshonak@elsevier.com